Generic Name and Formulations:
Diphtheria and tetanus toxoids, acellular pertussis; aluminum phosphate adsorbed + inactivated poliovirus vaccine; susp for IM inj; contains 2-phenoxyethanol, and residual amounts of formaldehyde, glutaraldehyde, bovine serum albumin, neomycin, polymyxin B; preservative-free.
Sanofi Pasteur, Inc.
Indications for QUADRACEL:
Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in children 4–6yrs of age: as 5th dose in DTaP series or as 4th or 5th dose in the IPV series following 4 doses of Pentacel and/or Daptacel.
<4yrs or >6yrs: not established. 4–6yrs: Each dose is 0.5mL IM, given once into deltoid muscle.
Anaphylaxis associated with any previous dose or component. Encephalopathy within 7 days of a previous pertussis-containing vaccine. Progressive neurologic disorders (eg, infantile spasms, uncontrolled epilepsy, or progressive encephalopathy).
Fever (≥105°F within 48 hours), persistent inconsolable crying (≥3 hours within 48 hours), shock (within 48 hours), seizures (within 3 days), Guillain-Barre Syndrome (within 6 weeks) of previous tetanus toxoid-containing vaccine. Immunocompromised. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C).
DTaP + IPV.
Concomitant vaccines: see full labeling. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Inj site reactions (eg, pain, increase in arm circumference, erythema, swelling), mylagia, malaise, headache, fever.
Single-dose vials (0.5mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML